ADMA Biologics Inc (NASDAQ:ADMA) Stock Rated “Moderate Buy” by Wall Street Analysts

ADMA Biologics Inc (NASDAQ:ADMA) has been given an average rating of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.50.

A number of equities analysts have recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 2nd. Mizuho set a $18.00 price objective on ADMA Biologics in a research note on Thursday. Finally, Cantor Fitzgerald lifted their price objective on ADMA Biologics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $13.21 on Friday. The firm has a market cap of $2.96 billion, a P/E ratio of 13.61 and a beta of 0.65. The firm’s 50-day simple moving average is $10.14 and its 200-day simple moving average is $10.91. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $20.46. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.03. The firm had revenue of $141.10 million during the quarter, compared to analyst estimates of $138.11 million. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.89%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 earnings per share. As a group, research analysts expect that ADMA Biologics will post 0.78 EPS for the current fiscal year.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Third-quarter revenue was $141.1 million, above the roughly $138.1 million analyst estimate and up 5% year over year. Adjusted EPS of $0.23 also topped expectations; GAAP net income increased 37% to $49.9 million. Company third-quarter results and business update
• Positive Sentiment: ASCENIV revenue rose 31% to $124.7 million, helping lift gross margin to 71%, about 14.5 percentage points higher year over year. The company also cited encouraging regulatory feedback on its SG-001 program. ASCENIV growth and quarterly performance
• Positive Sentiment: ADMA reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to at least $275 million, signaling greater confidence in profitability. 2026 revenue and EBITDA outlook
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $12 to $13 but maintained a neutral rating, suggesting the analyst sees limited near-term upside at the prevailing valuation. Cantor Fitzgerald rating update
• Negative Sentiment: BIVIGAM sales were weaker, tempering the product mix; however, ASCENIV’s growth more than offset that pressure in the reported quarter. Product sales discussion

Institutional Investors Weigh In On ADMA Biologics

Hedge funds have recently made changes to their positions in the company. Western Wealth Management LLC acquired a new position in shares of ADMA Biologics during the first quarter worth approximately $31,000. Rockefeller Capital Management L.P. raised its position in ADMA Biologics by 60.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 4,485 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 1,694 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in ADMA Biologics in the 2nd quarter worth approximately $42,000. Pinnacle Wealth Planning Services Inc. raised its position in ADMA Biologics by 33.1% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in ADMA Biologics in the 2nd quarter worth approximately $51,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.